3
Announcements
Trials
Browse
Landscape
Status
Terminated
2
Withdrawn
1
No longer available
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Thoracic
2
Plasma cell
1
Lymphoid
1
Conditions
Lymphoma, Large-Cell, Anaplastic
1
Granuloma, Plasma Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
fludarabine phosphate
3
venetoclax
2
navitoclax
2
fludarabine
2
zanubrutinib
1
sugemalimab
1
plerixafor
1
nilotinib
1
midostaurin
1
loncastuximab tesirine
1
eryaspase
1
ceritinib
1
asparaginase erwinia chrysanthemi recombinant
1
Whole-Body Irradiation
1
Tacrolimus
1
Mycophenolic Acid
1
Cytarabine
1
Cyclophosphamide
1
Cord Blood Stem Cell Transplantation
1
Busulfan
1
Brentuximab Vedotin
1
Bone Marrow Transplantation
1
Bendamustine Hydrochloride
1
Asparaginase
1
AP 1903 reagent
1
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
No longer available
×
ceritinib
×
Lymphoid
×
Clear all
NCT05100134
2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available